Status:
COMPLETED
A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate
Lead Sponsor:
Pfizer
Conditions:
Arthritis, Rheumatoid
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study is designed to provide safety and efficacy data to support the development of CP-690,550 in patients with moderate to severe rheumatoid arthritis on background of methotrexate.
Eligibility Criteria
Inclusion
- Adults with moderate to severe rheumatoid arthritis on a stable dose of methotrexate
Exclusion
- Pregnancy, severe acute or chronic medical conditions, including serious infections or clinically significant laboratory abnormalities.
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT00847613
Start Date
March 1 2009
End Date
February 1 2012
Last Update
May 16 2024
Active Locations (115)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Huntsville, Alabama, United States, 35801
2
Pfizer Investigational Site
Tucson, Arizona, United States, 85704
3
Pfizer Investigational Site
San Diego, California, United States, 92108
4
Pfizer Investigational Site
Santa Maria, California, United States, 93454